title: Clinical remission criteria for epithelial carcinoma of the ovary.
abstract: After primary cytoreductive surgery 188 patients with epithelial ovarian cancer were treated with combination chemotherapy between 1986 and 1989 in the Tokai Ovarian Tumor Study Group. Clinical remission criteria were set in this study and patients were examined to determine if they were in remission or not. Forty-seven cases (25%) had no remission and 85.9% of them died within 20 months after primary surgery. Fifty-seven cases (30.3%) had a remission and a subsequent recurrence. Eighty-four cases (44.7%) had no recurrence and all are currently alive. Independent remission factors by multivariate analysis were higher stage (P = 0.018), clear-cell carcinoma (P = 0.0048), larger maximum residual tumor (P = 0.0023), and PVB therapy (P = 0.026). Independent recurrence factors were higher stage (P = 0.0012), serous cystadenocarcinoma (P = 0.0001), clear-cell carcinoma (P = 0.00409), and PVB therapy (P = 0.0499). A significantly high remission rate and low recurrence rate was achieved using PVB therapy. This criteria has value for the treatment of epithelial ovarian carcinoma. The disease-free survival rate after clinical remission was the same as that after a negative second-look laparotomy, which implies that a second-look laparotomy may be unnecessary in the management of epithelial carcinoma of the ovary.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Morikawa
authors.forename: M
authors.initials: M
authors.lastname: Kawai
authors.forename: T
authors.initials: T
authors.lastname: Kano
authors.forename: F
authors.initials: F
authors.lastname: Kikkawa
authors.forename: H
authors.initials: H
authors.lastname: Oguchi
authors.forename: N
authors.initials: N
authors.lastname: Nakashima
authors.forename: T
authors.initials: T
authors.lastname: Ishizuka
authors.forename: Y
authors.initials: Y
authors.lastname: Furuhashi
authors.forename: S E
authors.initials: SE
authors.lastname: Hattori
authors.forename: K
authors.initials: K
authors.lastname: Kuzuya
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D004317:Doxorubicin / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D010752:Phosphoramide Mustards / Q000627:therapeutic use; D012074:Remission Induction; D012086:Reoperation; D015996:Survival Rate; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D010752:Phosphoramide Mustards; D001761:Bleomycin; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin